Why Truvada isn't being used for HIV prevention

Share this article:

On the penultimate day of 2013, the New York Times gave readers a deep dive on Gilead's Truvada for use in preventing HIV, or rather the lack thereof. As the Times notes, the combo drug has seen poor uptake among the gay community for that indication, 18 months after the strategy's FDA approval.

The lack of Truvada prescriptions—particularly among men—was attributed in part to “negative reactions” HCPs have reportedly given men when they brought it up, as well as social stigma: a particularly derogatory label has been used on social networks to describe men who are on the pill and purposefully engaging in risky behavior, NYT reports.

The article also addressed the absence of a public campaign to promote Truvada for prevention, its price, and side effects. Adherence issues, too, were called out.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.